Last Updated : May 17, 2023
Details
FilesProject Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Rapid Review
Project Number:
RC1481-000
Question
- What is the clinical effectiveness of bevacizumab in combination with chemotherapy followed by bevacizumab maintenance therapy for patients who have recurrent ovarian cancer and are platinum sensitive?
Key Message
It was not clear from the studies in this review whether bevacizumab plus chemotherapy does or does not improve overall survival compared to chemotherapy alone (or with placebo) for recurrent platinum-sensitive ovarian cancer.
Most studies in this review found that bevacizumab plus chemotherapy results in longer progression-free survival than chemotherapy alone (or with placebo) for recurrent platinum-sensitive ovarian cancer.
Most studies in this review found that bevacizumab plus chemotherapy had a more beneficial effect on treatment response than chemotherapy alone (or with placebo) for recurrent platinum-sensitive ovarian cancer.
There was no difference in quality of life, based on 1 randomized controlled trial, and no clear differences in adverse events reported between bevacizumab plus chemotherapy or chemotherapy alone (or with placebo).
Files
Last Updated : May 17, 2023